Axcella

📍 Cambridge, United States🗓 Founded 2010👥 17 employees💰 Last funded Oct 2022
Biotechnology Research🌐 axcellatx.com
Website LinkedIn
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence, the treatment of Long COVID, and the treatment of non-alcoholic steatohepatitis (NASH). The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.
6
Total investors
0
Early stage
1
Mid stage
4
Late stage
2010
Founded

Investors

6 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
6
Investor activity2014–2022 · investors recorded per year
2014120181201922020120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Axcella?
Axcella has 6 investors on record on gritt.io, 1 mid-stage and 4 late-stage investors.
When did Axcella last raise funding?
The most recent investment in Axcella recorded on gritt.io was in October 2022.
When was Axcella founded?
Axcella was founded in 2010.
What industry is Axcella in?
Axcella operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Axcella based?
Axcella is headquartered in Cambridge, United States.